Robuta

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-effect-having-trastuzumab-or-lapatinib-before-surgery-early-breast-cancer-ephos-b Cancer Research UK | A trial looking at the effect of having trastuzumab or lapatinib before... This trial was for people whose breast cancer had tested positive for the HER2 protein. This is HER2 positive breast cancer. https://adisinsight.springer.com/trials/700038657?error=cookies_not_supported&code=8a377667-dff8-46d5-82e8-db5e7459b6c9 A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the... This non-inferiority trial is comparing the efficacy and tolerability of neratinib [HKI-272; Wyeth] with lapatinib [Tykerb, Tyverb] + capecitabine [Xeloda] in https://scholars.duke.edu/publication/1407161 Scholars@Duke publication: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on... publication impact https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-lapatinib-before-surgery-for-breast-cancer A trial looking at lapatinib before surgery for breast cancer This trial looked at having a drug called lapatinib before surgery for breast cancer. looking atbefore surgerytriallapatinibbreast https://pubmed.ncbi.nlm.nih.gov/24075779/ Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in... In 2009 a prospective, randomized Phase II trial (NCT00842998) was initiated to evaluate the activity of HER2-targeting agents without chemotherapy (CT) in... https://pubmed.ncbi.nlm.nih.gov/40712104/ Elucidating Molecular Mechanisms of Drug-Induced Hepatotoxicity of Lapatinib DILI (drug-induced liver injury) remains a critical liability in drug discovery and development. However, there are few in vitro and preclinical models to... molecularmechanismsdruginducedhepatotoxicity https://scholars.duke.edu/publication/760976 Scholars@Duke publication: Single-agent lapatinib for HER2-overexpressing advanced or metastatic... single agent https://pubmed.ncbi.nlm.nih.gov/22123186/ Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast... Combined L + T treatment provides a more complete and stable inhibition of the HER network. With sustained HER2 inhibition, ER functions as a key... https://scholars.duke.edu/publication/1111413 Scholars@Duke publication: Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor... https://experts.mcmaster.ca/scholarly-works/194983 Lapatinib or Trastuzumab Plus Taxane Therapy for... Learn about the scholarly work entitled Lapatinib or Trastuzumab Plus Taxane Therapy for... lapatinibtrastuzumabplustherapy https://scholars.duke.edu/publication/760955 Scholars@Duke publication: Overall survival benefit with lapatinib in combination with trastuzumab... overall survivalscholarsdukepublication https://pubmed.ncbi.nlm.nih.gov/41933741/ CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to... The combination of doxorubicin (DOX) and lapatinib (LAP) enhances the antitumor efficacy of breast cancer. However, previous studies indicated that this... https://scholars.uky.edu/en/publications/lapatinib-and-poziotinib-overcome-abcb1-mediated-paclitaxel-resis/ Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer -... lapatinibovercome https://experts.arizona.edu/en/publications/chromosome-17-polysomy-without-her2-amplification-does-not-predic/ Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in... https://tobias-lib.uni-tuebingen.de/xmlui/handle/10900/156790 Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive... https://www.news-medical.net/news/2007/06/05/25996.aspx Drug lapatinib shows activity against brain metastases Jun 6, 2007 - The drug lapatinib shrank tumors and slowed progression of brain metastases in some patients with advanced breast cancer, according to results of a clinical... druglapatinibshowsactivitybrain https://pubmed.ncbi.nlm.nih.gov/18472989/ A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer Breast cancer remains a leading cause of disease and death among women throughout the world. Despite advances in drug therapy, development of novel and... https://pubmed.ncbi.nlm.nih.gov/22689807/ Overall survival benefit with lapatinib in combination with trastuzumab for patients with human... These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients... overall survivalfor patientsbenefitlapatinib https://scholars.duke.edu/publication/760969 Scholars@Duke publication: Randomized study of Lapatinib alone or in combination with trastuzumab... https://pubmed.ncbi.nlm.nih.gov/27073542/?dopt=Abstract Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates... The epithelial-mesenchymal transition (EMT) is a key developmental program that is often activated during cancer progression, and may promote resistance of... squamous cell carcinomalapatinibinducedepithelialtransition https://scholars.duke.edu/publication/760979 Scholars@Duke publication: A phase II study of lapatinib monotherapy in chemotherapy-refractory... https://portal.fis.tum.de/en/publications/lapatinib-versus-lapatinib-plus-capecitabine-as-second-line-treat/ Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth... second line https://pubmed.ncbi.nlm.nih.gov/25550597/ Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following... Lapatinib-plus-PLD is active and safe in HER2-positive MBC, especially suitable for patients with cardiological risk or brain metastases. https://adisinsight.springer.com/trials/700057858?error=cookies_not_supported&code=08ae7530-4bd8-4c1d-a5c5-a9a448a98429 Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab... This study is investigating the efficacy and tolerability of early versus late lapatinib + capecitabine, initiated immediately after progression on trastuzumab clinical outcomes https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-lapatinib-trastuzumab-docetaxel-her-2-positive-breast-cancer-lapatax A trial looking at lapatinib, trastuzumab and chemotherapy before surgery for breast cancer... This trial looked at lapatinib, trastuzumab and chemotherapy before surgery for breast cancer.